文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

不确定潜能克隆性造血与严重退行性主动脉瓣狭窄或慢性缺血后心衰患者炎症基因表达的相关性

Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该假设生成性诊断研究对8例严重退行性主动脉瓣狭窄、6例慢性心肌梗死后心衰患者及3例年龄匹配健康对照的外周单核细胞进行单细胞RNA测序,发现携带DNMT3A或TET2的CHIP驱动序列变异者单核细胞中IL-1β、IL-6受体、NLRP3炎症小体及CD163表达升高,提示其单核细胞处于促炎预激状态。

要点

  • 严重退行性主动脉瓣狭窄或慢性心梗后心衰患者中,CHIP驱动变异与单核细胞促炎基因表达上调相关。
  • DNMT3A或TET2 CHIP驱动变异者IL-1β、IL-6受体及NLRP3炎症小体表达显著升高。
  • 携带CHIP驱动变异的心血管病患者单核细胞可能对过度炎症反应预激。

核心结论

  • 携带CHIP驱动序列变异且患有心血管疾病的个体,其单核细胞似乎对过度炎症反应预激。

研究设计与样本

  • 假设生成性诊断研究,纳入8例严重退行性主动脉瓣狭窄、6例慢性心肌梗死后心衰患者及3例年龄匹配健康对照,于2017至2019年进行单细胞RNA测序分析外周单核细胞转录组。

主要发现

  • 携带DNMT3A或TET2 CHIP驱动序列变异者单核细胞IL-1β表达升高(无CHIP驱动变异1.6217 nUMI;DNMT3A 5.3956 nUMI,P < .001;TET2 10.8216 nUMI,P < .001)。
  • IL-6受体表达升高(无CHIP驱动变异0.5386 nUMI;DNMT3A 0.9162 nUMI,P < .001;TET2 0.5738 nUMI,P < .001)。
  • NLRP3炎症小体复合物表达升高(无CHIP驱动变异0.4797 nUMI;DNMT3A 0.9961 nUMI,P < .001;TET2 1.2189 nUMI,P < .001)。
  • CD163表达上调(无CHIP驱动变异0.5239 nUMI;DNMT3A 1.4722 nUMI,P < .001;TET2 1.0684 nUMI,P < .001)。
  • 基因本体分析显示DNMT3A或TET2 CHIP驱动变异者单核细胞中白细胞活化及白细胞介素信号通路基因显著上调。

关键数值与推荐

  • CHIP驱动基因变异等位基因频率均值:DNMT3A为4.2%(范围2.5%-6.9%),TET2为14.3%(范围2.6%-37.4%)。

临床怎么用

  • 对携带CHIP驱动变异的心血管病患者,需关注其单核细胞促炎预激状态及潜在过度炎症反应风险。

局限性

  • 样本量小(仅17例),为假设生成性研究,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cytokine release syndrome is a complication of coronavirus disease 2019. Clinically, advanced age and cardiovascular comorbidities are the most important risk factors. OBJECTIVE: To determine whether clonal hematopoiesis of indeterminate potential (CHIP), an age-associated condition with excess cardiovascular risk defined as the presence of an expanded, mutated somatic blood cell clone in persons without other hematological abnormalities, may be associated with an inflammatory gene expression sensitizing monocytes to aggravated immune responses. DESIGN, SETTING, AND PARTICIPANTS: This hypothesis-generating diagnostic study examined a cohort of patients with severe degenerative aortic valve stenosis or chronic postinfarction heart failure, as well as age-matched healthy control participants. Single-cell RNA sequencing and analyses of circulating peripheral monocytes was done between 2017 and 2019 to assess the transcriptome of circulating monocytes. EXPOSURES: Severe degenerative aortic valve stenosis or chronic postinfarction heart failure. MAIN OUTCOMES AND MEASURES: CHIP-driver sequence variations in monocytes with a proinflammatory signature of genes involved in cytokine release syndrome. RESULTS: The study included 8 patients with severe degenerative aortic valve stenosis, 6 with chronic postinfarction heart failure, and 3 healthy control participants. Their mean age was 75.7 (range, 54-89) years, and 6 were women. Mean CHIP-driver gene variant allele frequency was 4.2% (range, 2.5%-6.9%) for DNMT3A and 14.3% (range, 2.6%-37.4%) for TET2. Participants with DNMT3A or TET2 CHIP-driver sequence variations displayed increased expression of interleukin 1β (no CHIP-driver sequence variations, 1.6217 normalized Unique Molecular Identifiers [nUMI]; DNMT3A, 5.3956 nUMI; P < .001; TET2, 10.8216 nUMI; P < .001), the interleukin 6 receptor (no CHIP-driver sequence variations, 0.5386 nUMI; DNMT3A, 0.9162 nUMI; P < .001;TET2, 0.5738 nUMI; P < .001), as well as the NLRP3 inflammasome complex (no CHIP-driver sequence variations, 0.4797 nUMI; DNMT3A, 0.9961 nUMI; P < .001; TET2, 1.2189 nUMI; P < .001), plus upregulation of CD163 (no CHIP-driver sequence variations, 0.5239 nUMI; DNMT3A, 1.4722 nUMI; P < .001; TET2, 1.0684 nUMI; P < .001), a cellular receptor capable of mediating infection, macrophage activation syndrome, and other genes involved in cytokine response syndrome. Gene ontology term analyses of regulated genes revealed that the most significantly upregulated genes encode for leukocyte-activation and interleukin-signaling pathways in monocytes of individuals with DNMT3A (myeloid leukocyte activation: log[Q value], -50.1986; log P value, -54.5177; regulation of cytokine production: log[Q value], -21.0264; log P value, -24.1993; signaling by interleukins: log[Q value], -18.0710: log P value, -21.1597) or TET2 CHIP-driver sequence variations (immune response: log[Q value], -36.3673; log P value, -40.6864; regulation of cytokine production: log[Q value], -13.1733; log P value, -16.3463; signaling by interleukins: log[Q value], -12.6547: log P value, -15.7977). CONCLUSIONS AND RELEVANCE: Monocytes of individuals who carry CHIP-driver sequence variations and have cardiovascular disease appear to be primed for excessive inflammatory responses. Further studies are warranted to address potential adverse outcomes of coronavirus disease 2019 in patients with CHIP-driver sequence variations.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Abplanalp WT, Mas-Peiro S, Cremer S, et al. Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure. JAMA Cardiol. 2020. PMID: 32639511. doi:10.1001/jamacardio.2020.2468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。